摘要 |
There is disclosed an assay system for determining therapeutic activity for treating restenosis, atherosclerosis, chronic rejection syndrome and graft versus host disease (GVHD) by measuring inhibition of cell migration activit y in smooth muscle cells expressing a US28 receptor from the CMV genome. Specifically, there is disclosed a method for measuring inhibition of cell migration in isolated cells transfected with US28 or infected with CMV and stimulated with a ligand. There is further disclosed a method for treating atherosclerosis, restenosis, chronic rejection syndrome and graft versus hos t disease (GVHD), comprising administering an effective amount of an agent tha t is a US28 receptor antagonist, wherein a US28 receptor antagonist comprises an inhibitor compound that prevents transduction of US28 receptor signal stimulated by a US28 receptor ligand, wherein a US28 receptor ligand is selected from the group consisting of RANTES, MIP-1.alpha. and MCP. The invention further provides a method for treating restenosis, atherosclerosis , chronic rejection syndrome and GVHD by administering KHSV encoded vMIP-2, fractalkine or herbimycin.
|
申请人 |
OREGON HEALTH SCIENCE UNIVERSITY |
发明人 |
RUCHTI, FRONZISKA;SODERBERG-NAUCLER, CECILIA;SMITH, PATRICIA;NELSON, JAY;STREBLOW, DANIEL |